吲哚-2-乙酸乙酯 | 33588-64-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 吲哚-2-乙酸乙酯
• 中文别名: 2-(2-吲哚基)乙酸乙酯
• 英文名称: ethyl 2-(1H-indol-2-yl)acetate
• 英文别名: ethyl indole-2-acetate；ethyl 2-indolyl acetate；ethyl 1H-indol-2-ylacetate；ethyl 2-(indol-2-yl) acetate
• CAS: 33588-64-6
• 化学式: C₁₂H₁₃NO₂
• 分子量: 203.241
• InChiKey: FODUBFGFNKKYPU-UHFFFAOYSA-N

物化性质

• 熔点：
  28-31℃
• 沸点：
  118-120 °C(Press: 0.003 Torr)
• 密度：
  1.187

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8°C，干燥密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl indole-2-acetate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl indole-2-acetate
CAS number: 33588-64-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H13NO2
Molecular weight: 203.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  吲哚-2-乙酸乙酯 在 氢氧化钾 、 air 、 乙酸酐 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 为溶剂， 反应 151.17h， 生成 6,7,12,13-四氢-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5-酮
  参考文献：
  名称：

  Synthesis of the staurosporine aglycon

  摘要：

  A short synthesis of the staurosporine aglycon (6) is reported, the indolocarbazole skeleton being constructed by an intramolecular Diels-Alder reaction followed by a nitrene-mediated ring closure. The synthesis starts by acylation of ethyl indole-2-acetate with oxalyl chloride. The resulting indole-3-glyoxalyl chloride is quenched with 2-nitrocinnamylamine (29) to give the amide (31). Hydrolysis of the ester group and cyclodehydration then gives the pyranoindolone (35). On heating in bromobenzene, the pyranoindolone 35 undergoes intramolecular Diels-Alder reaction to give, after loss of carbon dioxide and air oxidation, the carbazole 36, which on treatment with triethyl phosphite cyclizes to the staurosporine aglycon. The overall yield from ethyl indole-2-acetate is 22.6%.

  DOI：

  10.1021/jo00033a036
• 作为产物：
  描述：

  甲基硝基苯 在 pyridinium chlorochromate 、 potassium hydroxide 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 35.0h， 生成 吲哚-2-乙酸乙酯
  参考文献：
  名称：

  通过烯醇与芳香硝基的分子内加成获得喹啉 1-氧化物的不寻常途径

  摘要：

  摘要 4-(2-硝基苯基)丁烯酸乙酯的混合物在催化量的叔丁醇钾存在下发生不寻常的分子内环化。

  DOI：

  10.1515/hc.2011.043

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Hetero-cope rearrangements - vI1 short and stereoselective syntheses of 2-vinylindoles by a tandem-process
  作者：Jochen Wilkens、Andrea Kühling、Siegfried Blechert

  DOI：10.1016/s0040-4020(01)90291-1

  日期：1987.1

  The initially formed N-phenylnitrone-intermediates are converted by a tandem-reaction (cycloaddition, Cope rearrangement, retro-Michael addition, and indolization) to 2-vinylindoles . Thus these indoles can be synthesized simply and stereoselectively in a one-pot reaction from N-phenylhydroxylamine , aldehydes , and electron-deficient allenes .

  最初形成的N-苯基硝酮中间体通过串联反应（环加成，Cope重排，逆迈克尔加成和吲哚化）转化为2-乙烯基吲哚。因此，这些吲哚可通过一锅反应由N-苯基羟胺，醛和缺电子的丙二烯简单和立体选择性地合成。
• Modulators of ATP-binding cassette transporters
  申请人：Hadida Ruah S. Sara

  公开号：US20070244159A1

  公开（公告）日：2007-10-18

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作调节ATP结合盒（“ABC”）转运蛋白或其片段的工具，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• Enantioselective Syntheses of <i>Strychnos</i> and <i>Chelidonium</i> Alkaloids through Regio‐ and Stereocontrolled Cooperative Catalysis
  作者：Luke S. Hutchings‐Goetz、Chao Yang、James W. B. Fyfe、Thomas N. Snaddon

  DOI：10.1002/anie.202005151

  日期：2020.9.28

  We describe enantioselective syntheses of strychnos and chelidonium alkaloids. In the first case, indole acetic acid esters were established as excellent partner nucleophiles for enantioselective cooperative isothiourea/Pd catalyzed α‐alkylation. This provides products containing indole‐bearing stereocenters in high yield and with excellent levels of enantioinduction in a manner that is notably independent

  我们描述的对映选择性合成马钱子和白屈菜生物碱。在第一种情况下，吲哚乙酸酯被确定为对映选择性协同异硫脲/ Pd催化α-烷基化的优秀伴侣亲核试剂。这提供了以高收率和出色的对映体诱导水平包含吲哚的立构中心的产品，其方式明显独立于N取代基。这导致了（−）‐ akuammicine和（−）‐ strychnine的简明合成。在第二种情况下，邻位表现不佳对映选择性协同异硫脲/ Ir催化的α-烷基化反应中的预取代肉桂酸亲电试剂可通过适当的取代基选择来克服，从而导致（+）-螯合碱，（+）-去甲螯合碱和（+）-螯合胺的对映选择性合成。